Cargando…

1359. Activity of Meropenem/Nacubactam Combination Against Gram-Negative Clinical Isolates: ROSCO Global Surveillance 2017

BACKGROUND: Nacubactam (NAC, OP0595, RG6080) is a novel member of the diazabicyclooctane inhibitor family with a dual mode of action, acting as a β-lactamase inhibitor and an antibacterial agent by means of PBP2 inactivation. NAC restores and extends the activity of β-lactam antibiotics, such as mer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okujava, Rusudan, Garcia-Alcalde, Fernando, Haldimann, Andreas, Zampaloni, Claudia, Morrissey, Ian, Magnet, Sophie, Kothari, Nimmi, Harding, Ian, Bradley, Kenneth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252560/ http://dx.doi.org/10.1093/ofid/ofy210.1190

Ejemplares similares

1368. Assessment of the In Vivo Efficacy of Human-Simulated Epithelial Lining Fluid (ELF) Exposure of Meropenem/Nacubactam (MEM/NAC) Combination Against β-Lactamase-Producing Enterobacteriaceae in Neutropenic Lung Infection Model
por: Asempa, Tomefa E, et al.
Publicado: (2018)

Safety and Pharmacokinetic Characterization of Nacubactam, a Novel β-Lactamase Inhibitor, Alone and in Combination with Meropenem, in Healthy Volunteers
por: Mallalieu, Navita L., et al.
Publicado: (2020)

698. Nacubactam Inhibits Class A β-lactamases
por: Barnes, Melissa D, et al.
Publicado: (2018)

2131. Activity of the Novel Antibiotic Zosurabalpin (RG6006) against Clinical Acinetobacter Isolates from China
por: Hawser, Stephen, et al.
Publicado: (2023)

In Vitro Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from U.S. and European Hospitals during 2014–2015
por: Morrissey, Ian, et al.
Publicado: (2019)

Roscoe's Chemistry Primer
Publicado: (1872)

The π-Circuit Technique in Coronary Surgery: Analysis of 1359 Consecutive Cases
por: Prapas, Sotirios N, et al.
Publicado: (2019)

Complete Genome Sequence of Carnobacterium gilichinskyi Strain WN1359(T) (DSM 27470(T))
por: Leonard, Michael T., et al.
Publicado: (2013)

2133. Surveillance of Eravacycline Against Gram-positive Clinical Pathogens, Including Resistant Isolates, Collected Worldwide From Multiple Infection Sites During 2021
por: Hawser, Stephen, et al.
Publicado: (2023)

1287. Pharmacokinetics, Safety, and Tolerability of Nacubactam after Single Coadministration with β-Lactams in Japanese Healthy Subjects
por: Asano, Masayo, et al.
Publicado: (2020)

The Place of Meropenem–Vaborbactam in the Management of Carbapenem-Resistant Gram-Negative Infections
por: Chopra, Teena
Publicado: (2021)

1359. Clinical Experience and Challenges Utilizing Clofazimine in the Treatment of Nontuberculous Mycobacterial Pulmonary Infections
por: Mercurio, Amanda, et al.
Publicado: (2019)

Propranolol restores susceptibility of XDR Gram-negative pathogens to meropenem and Meropenem combination has been evaluated with either tigecycline or amikacin
por: Mabrouk, Samar S., et al.
Publicado: (2023)

Standardization of Alpinia calcarata Roscoe rhizomes
por: Arambewela, L. S. R., et al.
Publicado: (2010)

Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae
por: Igarashi, Yuki, et al.
Publicado: (2023)

2136. In Vitro Activity of Nacubactam (OP0595) Combined with Cefepime against Carbapenem-resistant Enterobacterales Isolated in Japan
por: Yanagihara, Katsunori, et al.
Publicado: (2023)

Discovering the DNA-Binding Consensus of the Thermus thermophilus HB8 Transcriptional Regulator TTHA1359
por: Teague, Josiah L., et al.
Publicado: (2021)

1359. Reported Neurologic, Ocular, and Otic Manifestations among Syphilis Cases — 16 States, 2019
por: Jackson, David A, et al.
Publicado: (2021)

628. Pharmacokinetics, Safety and Tolerability of Co-administration of Nacubactam and β-lactams after Multiple Doses in Japanese Healthy Subjects
por: Sato, Hiroki, et al.
Publicado: (2021)

In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017
por: Morrissey, Ian, et al.
Publicado: (2020)

Commentary: Bunsen-Roscoe reciprocity – Is it still valid?
por: Anitha, Venugopal, et al.
Publicado: (2022)

G1359A Polymorphism of the Cannabinoid Receptor 1 Is Not Associated with Overweight and Dyslipidemia in Young Northeastern Mexicans
por: Rodríguez-Rodríguez, Ismael, et al.
Publicado: (2019)

1359. Utilization of West Virginia Pediatric Medicaid Claims Data to Guide Outpatient Antimicrobial Stewardship Interventions
por: Kilgore, Jacob T, et al.
Publicado: (2020)

1359. Understanding Data Completeness from Sites Participating in the N3C Limited Data Set
por: Koren, Yuval, et al.
Publicado: (2023)

In Vitro Activity of Eravacycline against Gram-Positive Bacteria Isolated in Clinical Laboratories Worldwide from 2013 to 2017
por: Morrissey, Ian, et al.
Publicado: (2020)

915. Global 2018 Surveillance of Eravacycline Against Gram-positive Pathogens, Including Resistant Isolates
por: Morgan, Steven, et al.
Publicado: (2020)

Bioactive Compounds and Bioactivities of Ginger (Zingiber officinale Roscoe)
por: Mao, Qian-Qian, et al.
Publicado: (2019)

Research Progress on Chemical Constituents of Zingiber officinale Roscoe
por: Liu, Yan, et al.
Publicado: (2019)

P1359: TUMOR-SPECIFIC, T-CELL-TARGETING MICRORNA IS ASSOCIATED WITH CART CELL FAILURE IN B CELL MALIGNANCIES
por: Chohan, Karan, et al.
Publicado: (2023)

1279. In Vitro Activity of Nacubactam (OP0595) Alone and in Combination with β-Lactams against β-Lactamase-Producing Enterobacterales Isolated in Japan
por: Nagira, Yu, et al.
Publicado: (2020)

In Vivo Pharmacodynamics of β-Lactams/Nacubactam against Carbapenem-Resistant and/or Carbapenemase-Producing Enterobacter cloacae and Klebsiella pneumoniae in Murine Pneumonia Model
por: Hagihara, Mao, et al.
Publicado: (2021)

Thiol-Containing Metallo-β-Lactamase Inhibitors Resensitize Resistant Gram-Negative Bacteria to Meropenem
por: Tehrani, Kamaleddin Haj Mohammad Ebrahim, et al.
Publicado: (2017)

519. Multidrug-resistant Gram-Negative Bacteremia in Pediatric Patients: Is It Time to Change to Empiric Meropenem?
por: Mongkolrattanothai, Kanokporn, et al.
Publicado: (2019)

358. Surveillance of Activity of Antifungals: Data from the Analysis of Resistance in Antifungals (ARIA) 2020 Study
por: Hawser, Stephen, et al.
Publicado: (2022)

In vitro Activity of Fosfomycin, Alone and Combined with Cefepime and Meropenem, Against Carbapenemase-Producing Gram-Negative Bacteria
por: Wiederhold, Nathan P, et al.
Publicado: (2017)

Effect of extended infusion of meropenem and nebulized amikacin on Gram-negative multidrug-resistant ventilator-associated pneumonia
por: Ammar, Mona Ahmed, et al.
Publicado: (2018)

Role of phenotypic testing in determining the mechanism of resistance in Gram-negative bacilli & risk factors for meropenem resistance
por: Raja, Kavita, et al.
Publicado: (2019)

Einstein–Roscoe regression for the slag viscosity prediction problem in steelmaking
por: Saigo, Hiroto, et al.
Publicado: (2022)

1613. Global 2018 Surveillance of Eravacycline Against Gram-negative Pathogens, Including Multi-drug Resistant Isolates
por: Lijfrock, Virgil, et al.
Publicado: (2020)

Comparative evaluation of rRNA depletion procedures for the improved analysis of bacterial biofilm and mixed pathogen culture transcriptomes
por: Petrova, Olga E., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3cvie9s06ifvr1m5k2baall78b